Another tool to combat COVID-19: the Moderna vaccine is shown to be safe and efficacious among adolescents 12-17 years of age
In their recent publication in The New England Journal of Medicine, researchers Dr. Kashir Ali, Dr. Gary Berman and colleagues presented the interim results of the Moderna vaccine trial in adolescents aged 12 to 17.
Back-to-university checklist: books, pens, vaccine
Researchers from Ontario indicate that about 80% of students enrolled at a large Canadian university between June and October 2020, prior to the availability of vaccines, intended to receive a COVID-19 vaccine once it was offered.
Safety and immunogenicity of a “mix-and-match” vaccine strategy with the AstraZeneca and Pfizer-BioNTech vaccines
A new study published in The Lancet by researchers from Oxford University provides more in-depth safety and immunogenicity data to support a “mix-and-match” vaccine strategy, similar to the one currently used in Canada.
Breakthrough infections with the Delta variant in vaccinated individuals may be associated with lower levels of neutralizing antibodies.
Emergence of variants of concern (VOCs) may potentially impact efforts to end the COVID-19 pandemic, despite the ongoing continuation of the global vaccine rollout.
Meeting the need for Long COVID policies – call for action
According to a recent viewpoint in Science, around one in three people with symptomatic COVID-19 still experience symptoms 12 weeks after the onset of infection, an outcome known as Post-COVID Conditions or Long COVID.
Life course health outcomes of children born to mothers with COVID-19
Maternal COVID-19 infection has resulted in elevated rates of preterm birth and low birth weight. According to a recent publication in JAMA Pediatrics, exposure to maternal COVID-19 infection may have broader implications on newborns later in life, suggesting a potential risk for long-term health outcomes among these individuals.
How effective are the Pfizer and the AstraZeneca vaccines against the delta variant?
In a recent study published in the New England Journal of Medicine, researchers from the UK have estimated the effectiveness of vaccination in preventing symptomatic disease caused by the delta or alpha variants.
Long-term analysis of COVID-19 patients demonstrates durable and broad immune responses against SARS-CoV-2
While scientists are striving to identify the specific protection mechanisms against SARS-CoV-2, a recent publication in Cell Reports Medicine followed a group of 254 COVID-19-recovered individuals who were infected during the first surge of COVID-19 in Seattle and Atlanta.
Growing evidence for safety and effectiveness of mix-and-match COVID-19 vaccination
Mixing COVID-19 vaccine products has been done to maximize the number of people that can be fully vaccinated in settings where vaccine availability is limited or unpredictable.